Chemistry:Quilizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGHE |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10046N1728O2023S44 |
| Molar mass | 146082.49 g·mol−1 |
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.[1] It binds to IGHE.[2][3][4][5][6][7]
This drug was developed by Genentech.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Quilizumab, American Medical Association.
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106". WHO Drug Information 25 (4). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf.
- ↑ "A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria". J. Allergy Clin. Immunol. 138 (6): 1730–1732. December 2016. doi:10.1016/j.jaci.2016.06.023. PMID 27567329.
- ↑ "A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma". Respir. Res. 17: 29. March 2016. doi:10.1186/s12931-016-0347-2. PMID 26993628.
- ↑ "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production". Sci Transl Med 6 (243): 243ra85. July 2014. doi:10.1126/scitranslmed.3008961. PMID 24990880.
- ↑ "An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases". Curr Respir Med Rev 13 (1): 22–29. March 2017. doi:10.2174/1573398X13666170616110738. PMID 29290750.
- ↑ "Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria". J Allergy Clin Immunol Pract 6 (4): 1108–1117. 2018. doi:10.1016/j.jaip.2018.02.024. PMID 30033912.
 |  |
